Method of presenting oncology treatment outcomes influences patient treatment decision-making in metastatic colorectal cancer
- PMID: 16372152
- DOI: 10.1245/ASO.2006.03.086
Method of presenting oncology treatment outcomes influences patient treatment decision-making in metastatic colorectal cancer
Abstract
Background: The methods used to communicate relevant outcomes in oncology to patients will likely influence treatment decisions. The purpose of this study was to examine the influence of three different methods of describing the efficacy of therapy on treatment decisions regarding management of metastatic colorectal cancer.
Methods: Participants reviewed a clinical scenario and randomly received one of three ways of describing efficacy of chemotherapy in metastatic colorectal cancer: (1) relative risk reduction, (2) tumor response rate, and (3) median overall survival. They received the same clinical scenario but were presented four treatment options: (1) observation and supportive care, (2) chemotherapy, (3) surgery, and (4) surgery and chemotherapy and the accompanying median overall survival estimate.
Results: Participants included 102 preclinical medical students. In the first scenario, 85% chose chemotherapy in the relative risk reduction group, as did 88% of the tumor response rate group, but significantly fewer participants did so in the median overall survival group (35%; P < .001). In the second scenario, there was a significant difference in treatment preferences, with 4% of participants choosing observation/supportive care. None chose chemotherapy only, 19% chose surgery only, and 77% chose surgery plus chemotherapy (P < .001).
Conclusions: This study demonstrated that different methods of describing oncology treatment outcomes associated with therapy for metastatic colorectal cancer to the liver can have a dramatic effect on patient treatment decisions.
Comment in
-
Decision making for patients with colorectal cancer liver metastases.Ann Surg Oncol. 2006 Jan;13(1):10-1. doi: 10.1245/ASO.2006.09.913. Epub 2006 Jan 1. Ann Surg Oncol. 2006. PMID: 16372150 No abstract available.
Similar articles
-
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach.Dis Colon Rectum. 2006 Oct;49(10):1596-601. doi: 10.1007/s10350-006-0662-7. Dis Colon Rectum. 2006. PMID: 16988853
-
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47. doi: 10.1016/j.critrevonc.2007.12.003. Epub 2008 Feb 1. Crit Rev Oncol Hematol. 2008. PMID: 18243010
-
The treatment of hepatic metastases in colorectal carcinoma.Am Surg. 2006 Jun;72(6):466-73. Am Surg. 2006. PMID: 16808196 Review.
-
What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer.Dis Colon Rectum. 2003 Oct;46(10):1351-7. doi: 10.1097/01.DCR.0000084432.45536.83. Dis Colon Rectum. 2003. PMID: 14530674
-
[Chemotherapy and hepatectomy for liver metastasis from colorectal cancer].Gan To Kagaku Ryoho. 2009 Aug;36(8):1247-52. Gan To Kagaku Ryoho. 2009. PMID: 19692762 Review. Japanese.
Cited by
-
Controversies on the management of clinical situations with low therapeutic effectiveness in oncology.Clin Transl Oncol. 2010 Jul;12(7):493-8. doi: 10.1007/s12094-010-0542-4. Clin Transl Oncol. 2010. PMID: 20615826
-
Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?Curr Colorectal Cancer Rep. 2012 Jun;8(2):130-137. doi: 10.1007/s11888-012-0122-9. Epub 2012 Mar 17. Curr Colorectal Cancer Rep. 2012. PMID: 22611343 Free PMC article.
-
Using alternative statistical formats for presenting risks and risk reductions.Cochrane Database Syst Rev. 2011 Mar 16;2011(3):CD006776. doi: 10.1002/14651858.CD006776.pub2. Cochrane Database Syst Rev. 2011. PMID: 21412897 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical